Work

Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.2006

Authors: Myung-Ju Ahn, Dong-Wan Kim, Byoung Chul Cho, Sang-We Kim, Jong-Seok Lee, Jin Seok Ahn, Tae Min Kim, Chia-Chi Lin, HyeRyun Kim, Tom John, Stephen Chuan-Hao Kao, Jonathan Wade Goldman, Wu-Chou Su, Ronald B. Natale, Philip Overend, Zhenfan Yang, James Chih-Hsin Yang

Institutions: Samsung Medical Center, Sungkyunkwan University, Seoul National University Hospital, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Asan Medical Center, University of Ulsan, Seoul National University Bundang Hospital, National Taiwan University Hospital, Olivia Newton-John Cancer Research Institute, Chris O’Brien Lifehouse, University of California, Los Angeles, National Cheng Kung University Hospital, National Cheng Kung University, Cedars-Sinai Medical Center, AstraZeneca (United Kingdom)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2727135362

Cites:

Cited by: 17

Related to: 10